Company: SXTPW
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-014334
Chunk: 73

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-14
Form: S-1
Chunk 73
---
 of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success, in which case we may not generate significant revenues or become profitable. Physicians are often reluctant to switch their patients from existing therapies even when new and potentially more effective or convenient treatments enter the market. Further, patients often acclimate to the therapy that they are currently taking and do not want to switch unless their physicians recommend switching products or they are required to switch therapies due to lack of reimbursement for existing therapies. 41 Efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may not be successful. If any of our product candidates is approved but does not achieve an adequate level of market acceptance, we may not generate significant revenues and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:

| ● | the                                 
 efficacy and safety of the product; |

| ● | the                                                                    
 potential advantages of the product compared to competitive therapies; |

| ● | the                                          
 prevalence and severity of any side effects; |

| ● | the                                                     
 clinical indications for which the product is approved; |

| ● | whether                                                                                                    
 the product is designated under physician treatment guidelines as a first-, second- or third-line therapy; |

| ● | the                                                                                  
 product’s convenience and ease of administration compared to alternative treatments; |

| ● | the                                                                                               
 willingness of the target patient population to try, and of physicians to prescribe, the product; |

| ● | limitations                                                                                           
 or warnings, including distribution or use restrictions contained in the product’s approved labeling; |

| ● | the                                                      
 approval of other new products for the same indications; |

| ● | changes                                                                   
 in the standard of care for the targeted indications for the product; and |

| ● | availability                                                                                                      
 and amount of coverage and reimbursement from government payors, managed care plans and other third-party payors. |

Our future growth depends on our ability to successfully commercialize Arakoda, Tafenoquine (Arakoda or other regimen) for non-malaria prevention indications, Celgosivir and our other product candidates, and we can provide no assurance that we will successfully commercialize Arakoda, Tafenoquine (Arakoda or other regimen) for non-malaria prevention indications, Celgosivir and other product candidates. Our future growth depends on our ability to successfully commercial